Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23563256 | 0.95 | CYP1A2 (0.36) | SIGMAR1CYP1A2TSHRMEN1KMT2A | |
| SCHEMBL25647096 | 0.91 | SIGMAR1 (0.33) | SIGMAR1CYP1A2MEN1KMT2A | |
| SCHEMBL4527151 | 0.91 | CYP1A2 (0.33) | SIGMAR1CYP1A2TSHRMEN1KMT2A | |
| SCHEMBL4527146 | 0.91 | CYP1A2 (0.33) | SIGMAR1CYP1A2TSHRMEN1KMT2A | |
| SCHEMBL23982594 | 0.88 | — | — | |
| SCHEMBL29558324 | 0.87 | KMT2A (0.33) | MEN1KMT2ARAB9A | |
| SCHEMBL1120699 | 0.87 | KMT2A (0.33) | MEN1KMT2ARAB9A | |
| SCHEMBL1120701 | 0.87 | KMT2A (0.33) | MEN1KMT2ARAB9A | |
| SCHEMBL14280782 | 0.86 | CYP1A2 (0.36) | SIGMAR1CYP1A2MEN1KMT2A | |
| SCHEMBL9952467 | 0.86 | KMT2A (0.33) | MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738334-B2 | Supported catalyst systems and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11718635-B2 | Iron bis(imino) aryl catalysts and methods thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230174757-A1 | Linear Low Density Polyethylene for Film Applications | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021126692-A1 | IRON BIS(IMINO) ARYL CATALYSTS AND METHODS THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718635-B2 | Iron bis(imino) aryl catalysts and methods thereof | IDO2, SLC40A1, IDO1 | SIGMAR1 295/4885CYP1A2 1635/4885TSHR 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.